High Risk Neuroblastoma clinical trials

Explore recruiting high risk neuroblastoma clinical trials.

Recruiting high risk neuroblastoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

High Risk Neuroblastoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma

Spain, France, Denmark, Ireland, Germany

Phase II and Phase III (Integrated) EU CTIS Study details

HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN : Randomised, international and multicentric phase 3 study that evaluates 3 therapeutic phases (induction, high-dose chemotherapy and radiotherapy) for patients with high-risk neuroblastoma, and introduces chemoimmunotherapy for patients with insufficient metastatic response after induction chemotherapy

Netherlands, Spain, Denmark, Norway, Germany, Czechia +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma LuDO-N

Denmark, Norway, Lithuania, Netherlands, Sweden, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

TCRaß+CD19+ depleted haploidentical stem cell transplantation followed by immunotherapy in patients with relapsed/resistant high-risk neuroblastoma

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase Ib study combining dinutuximab beta with induction chemotherapy regimens in patients with newly diagnosed high-risk neuroblastoma: SIOPEN-Pilot01

Netherlands, France, Germany, Spain, Austria, Italy +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

High Risk Neuroblastoma trials by city

High Risk Neuroblastoma in Toronto High Risk Neuroblastoma in Vancouver High Risk Neuroblastoma in Montreal High Risk Neuroblastoma in Calgary High Risk Neuroblastoma in Edmonton High Risk Neuroblastoma in Ottawa High Risk Neuroblastoma in Winnipeg High Risk Neuroblastoma in Quebec City High Risk Neuroblastoma in Hamilton High Risk Neuroblastoma in Kitchener High Risk Neuroblastoma in London High Risk Neuroblastoma in Halifax High Risk Neuroblastoma in New York High Risk Neuroblastoma in Los Angeles High Risk Neuroblastoma in Chicago High Risk Neuroblastoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease